Browse

Search for: rheumatoid arthritis    methotrexate    autoimmune disease    biomarker    gene expression    GWAS    HLA genes    non-HLA genes   

ID PMID Title PublicationDate abstract
7473478 Hydroxychloroquine in the treatment of erosive osteoarthritis. 1995 Aug OBJECTIVE: Hydroxychloroquine has been used successfully in the treatment of inflammatory arthritides such as rheumatoid arthritis and systemic lupus erythematosus, and less commonly in the seronegative spondyloarthropathies. Our objective was to determine the effectiveness of hydroxy-chloroquine in inflammatory or erosive osteoarthritis (OA). METHODS: We retrospectively reviewed clinical records of 8 patients prescribed hydroxychloroquine therapy whose symptoms of erosive OA were unresponsive to nonsteroidal antiinflammatory drugs (NSAID). RESULTS: Hydroxychloroquine was effective in 6 of the 8 patients treated; it was well tolerated by all patients. CONCLUSION: The use of hydroxychloroquine in patients with erosive OA unresponsive to NSAID appears promising. Prospective studies are needed to confirm our observations.
7788662 [Pulse therapy in diffuse connective tissue diseases]. 1995 May 31 Methods of i.v. pulsed treatment using methyl prednisolone, cyclophosphamide or polyvalent immunoglobulin made it possible to suppress rapidly and effectively the activity of prognostically serious (clinical and laboratory) manifestations in diffuse connective tissue diseases (systemic autoimmune diseases). The author presents a general justification of this therapeutic method with emphasis on the immunogenetics of pathological autoimmunity (autogenes, apoptosis), he describes methodical aspects, the asset and partial clinical indications in rheumatoid arthritis, systemic lupus erythematosus, polymyositis and dermatomyositis, and primary systemic vasculitis. The author mentions also prerequisites of further development of i.v. pulsed treatment in diffuse connective tissue diseases.
7564565 On the role of the peroxisome in ontogeny, ageing and degenerative disease. 1995 May 12 This article reviews the available data on the role of the peroxisome in the growth, differentiation and degeneration of mammalian tissues. Developmental progressions of peroxisomes are described, along with the influence of inhibitors of peroxisomal enzymes, peroxisome proliferators and morphogenetic agents on the ontogeny of experimental animals. The role of the peroxisome in protecting tissues from damage by oxygen free radicals is also described, as is the changing role of the peroxisome in the ageing animal. Amongst the degenerative diseases which have been associated with free radical damage are cancer, atherosclerosis, muscular dystrophy, rheumatoid arthritis and the senile degeneration of brain function. In all these conditions, the major characteristics of molecular damage have been considered, along with the particular role of the peroxisome in alleviating these effects. Proposals for further research into peroxisomal function during ontogeny and the degenerative changes associated with ageing are developed, and the possibility of palliative treatments discussed.
11362590 Treatment for HIV-related inflammation. 1995 May
8527225 Erythropoietin. 1995 Erythropoietin (Epo), the first growth factor to be discovered, is an endocrine hormone produced by specialized renal cells. The rate of Epo production is determined primarily by the oxygen demands of these renal cells relative to their oxygen supply. However, Epo production is modulated by various hormones, nutritional factors, cytokines, and the integrity of the erythron. Epo interacts with specific receptors found almost exclusively on erythroid progenitors. This interaction results in an expansion of the number of the erythroid progenitor and triggers late committed progenitors to undergo terminal maturation when provided with essential nutrients. Recombinant human Epo (rHuEpo) is commercially available for human use. It is safe, easily administered, and almost universally effective in treating the anemia of patients with renal failure. It has also been successful in treating the anemia of some patients with neoplasms, myelodysplastic syndromes, HIV infection, rheumatoid arthritis, and aplastic anemia. Much remains to be learned about the regulation of Epo production, the physiologic actions of Epo, and how best to use this growth factor in the treatment of anemia.
7598502 Targets for antiinflammatory drugs. 1995 Aspirin-like nonsteroidal antiinflammatory agents, corticosteroids, and methotrexate are the mainstays of therapy in rheumatoid arthritis and other inflammatory diseases. It is now clear that these agents share at least one characteristic: All of these agents diminish the adhesive interactions required for the accumulation of white blood cells at an inflamed site. We discuss the biochemical and functional mechanisms by which these drugs alter the inflammatory response, and the potential for development of new antiinflammatory agents based upon these pharmacological actions.
7955690 Pseudothrombophlebitis in an adolescent without rheumatic disease. A case report. 1994 Nov Pseudothrombophlebitis syndrome is the occurrence of calf pain and swelling caused by extrinsic compression of the popliteal vessels by an enlarging Baker's cyst or by calf inflammation that occurs as the result of a ruptured Baker's cyst. Few cases of pseudothrombophlebitis syndrome have been reported in patients less than 18 years of age, and nearly all these young patients had juvenile rheumatoid arthritis. Reported here is the case of a 17-year-old male patient without rheumatic disease who presented to the outpatient clinic with a 1-week history of an increasingly painful swelling of the right calf without any history of precipitating factors for a deep vein thrombosis.
7521270 Diagnostic and therapeutic applications of angiogenesis research. 1993 Sep Certain principles of the angiogenic process elucidated in the laboratory over the past 3 decades have now been translated to clinical application. These applications are in the areas of prognosis, inhibition of angiogenesis, and acceleration of angiogenesis. As more experience is gained from these studies we may begin to see the development of therapies for many other angiogenic diseases, including diabetic retinopathy, rheumatoid arthritis, and psoriasis. It may be possible to increase the rate of neovascularization of a myocardial infarction and perhaps even to stimulate the growth of coronary collateral vessels. From these laboratory and clinical studies it has become clear that angiogenesis is a fundamental process that dominates diseases in many different branches of medicine and surgery. A clear understanding of the biological and molecular aspects of this process will be critical to the successful treatment of a wide spectrum of "angiogenic diseases" [53].
8796888 Monocyte chemoattractant protein 1: a potential regulator of monocyte recruitment in infla 1996 May The appearance of specific types of leukocytes in inflammatory infiltrates may be governed by cell-specific chemoattractants called chemokines. In particular, monocyte chemoattractant protein 1 (MCP-1) has been implicated in diseases characterized by monocyte-rich infiltrates, including atherosclerosis, rheumatoid arthritis and multiple sclerosis. While we are beginning to understand the structural determinants that govern the activities of MCP-1 in vitro, we know much less about its physiological functions in vivo and its pathogenetic role in disease. However, recent data from genetically modified mice have begun to place MCP-1 in a central position in monocyte trafficking and activation.
7892122 [Cytokines and skin diseases]. 1995 Many skin diseases such as eczema and psoriasis are characterised by a chronic inflammatory skin condition. In this respect they resemble other chronic diseases such as rheumatoid arthritis, bronchial asthma, ulcerous colitis and Crohn's disease. A persistent accumulation, predominantly of T-lymphocytes constitutes the central pathophysiological feature of such diseases. The past 15-20 years have witnessed the characterisation of an extensive series of peptides known as cytokines. These are soluble, relatively low molecular weight peptides which at low concentrations mediate regulation of cellular receptors, new phenotype expression, secretion and migration. Many cytokines have been found to be present in conjunction with skin diseases, and it is suggested that they are involved in the development of inflammation.
8203699 The utility of HMO data for the surveillance of chronic diseases. 1994 Jun In an area served by a single medical center that operates as both health maintenance organization (HMO) and fee-for-service clinic, we reviewed existing computerized medical records to determine the prevalence of 11 diseases. Standardized medical care utilization prevalence ratios, comparing the annual prevalences in the two groups, varied from 1.38 for rheumatoid arthritis to 0.60 for liver cirrhosis. Unless supplemented by data from hospitals, physicians, and other sources, HMO data may result in invalid estimates of the prevalence of chronic disease.
8372847 De novo amyloidosis in a renal allograft: a case report and review of the literature. 1993 Sep Recurrent amyloidosis is an uncommon but well-documented event in up to 26% of renal allograft recipients transplanted for amyloid renal disease. Both primary and secondary amyloidoses recur. De novo primary and secondary amyloid have not been previously reported. We report the first occurrence of de novo secondary amyloid in a renal allograft recipient. The cause of the secondary amyloidosis is unproven, but possible etiologies include inflammation secondary to occult hepatitis, rheumatoid arthritis, or chronic rejection. Colchicine therapy has not resulted in decreased proteinuria or improved renal function.
8366806 Magnetic resonance microscopy in rat skeletal research. 1993 Aug Noninvasive evaluation of skeletal tissue, particularly certain sites that tend to be predisposed to disease, is critical in understanding the pathogenesis, progression, and successful treatment of various diseases like osteoporosis, rheumatoid arthritis, and osteoarthritis. Although several noninvasive techniques are currently available to evaluate skeletal tissues, they all have critical limitations. We report here a systematic study to compare the morphological changes (overall profile and tissue architecture) in the proximal tibiae and coccygeal vertebrae of a young growing rat and an older retired female breeder rat using 2- and 3-dimensional MR (magnetic resonance) microscopy and histology. We have obtained MR microimages of intact rat tibiae and vertebrae with resolution upto 24 24 250 microns and have found excellent correlations between MR microscopy results and histological assessment.
8309826 [Mixed connective tissue disease in a male patient chronically exposed to toxic chemicals] 1993 May 3 A case of the mixed disease of the connective tissue (MCTD) in male patient occupationally exposed to PVC and other toxic agents is presented. Clinical symptoms consisted of the typical signs of SLE, rheumatoid arthritis and lupoid hepatitis. MCTD diagnosis was confirmed serologically by the presence of autoantibodies anti-RNP. Prednisone administered in the daily dose of 60 mg produced remission.
7685046 Microglia and immune activation in Alzheimer's disease. 1993 Apr Although the brain has been traditionally viewed as immunologically privileged, it is now clear that the brain is surveyed by T lymphocytes, that resident brain microglia express immune-related antigens and can function as antigen-presenting cells, and that glial cells can synthesize and respond to cytokines, once viewed as immune system specific regulators. Alzheimer's disease is associated with increased expression of several immune-related markers in brain, including MHC class II antigens, complement factors and their receptors, and acute-phase proteins. Preliminary epidemiological evidence suggests that patients on long-term anti-inflammatory drug therapy for rheumatoid arthritis have an unexpectedly low incidence of Alzheimer's disease.
8441145 Mucolipidosis III presenting as a rheumatological disorder. 1993 Jan Genetic disorders of the osseous skeleton constitute a challenging area of differential diagnosis. Three patients, 2 girls and 1 boy, were referred to our pediatric rheumatology clinic because of progressive stiffness of their hands and flexion contractures of fingers, accompanied by additional musculoskeletal changes. One of the girls had been diagnosed in early childhood as having juvenile rheumatoid arthritis, the other was suspected to have scleroderma, and the boy had been labelled with "Hurler's syndrome." On evaluation, all 3 patients had the clinical and roentgenographic features of mucolipidosis III; the diagnosis of mucolipidosis III was confirmed by enzymatic assays. We call for an awareness of pediatricians, rheumatologists and orthopedic surgeons to the "rheumatological" presentation of mucolipidosis III. The establishment of a precise diagnosis will lead to adequate management and will allow appropriate genetic counseling.
8435297 Rheumatic manifestations of neoplasia. 1993 Jan Recent literature on the rheumatic manifestations of neoplasia has again focused on the increased association of Sjögren's syndrome and rheumatoid arthritis with lymphoproliferative malignancies and leukemias. A series of 13 patients with monocytoid B-cell lymphoma, a recently described variant of low-grade B-cell lymphoma, and Sjögren's syndrome was reported. The skeletal manifestations of leukemias are extensively reviewed emphasizing that osteoarticular manifestations may predate the hematologic disease. A case of monoarthritis of the knee as a manifestation of chronic leukemia is presented in which synovial biopsy revealed a leukemic infiltrate. Recent studies looking at the association of polymyositis and dermatomyositis with malignancy challenge this link. Two cases of malignancy presenting with polyarthritis are reviewed, and in both cases the polyarthritis resolved with removal of the tumor. A case report and a series of synovial sarcomas are also reviewed. Hodgkin's disease can initially present with skeletal involvement; six cases are reviewed.
1483314 Elastolytic activity of human monocytes: rheumatological aspects. 1992 Nov Activation of human monocytes in rheumatic disorders includes the production of substances active in immunologic interactions, inflammatory responses, and tissue remodelling. This review discusses the cell surface-related elastolytic activity of live human monocytes, as determined by a newly developed elastin assay. Elastase activity was not found to be depressed by patient treatment with glucocorticoids or slow-acting disease modifying drugs nor enhanced by phagocytosis, but was increased by immune complexes in vitro and in patients with rheumatoid arthritis or giant cell arteritis. The leucocyte elastase content seems to be influenced by systemic factors before the monocytes are released into the blood. The enzyme expression of elastase is determined by local factors acting after the cells have left the circulation. Monocyte expression may therefore be a link between immune activation and proteolytic activity.
1434818 Autoimmunity and auto-immune syndromes associated with and preceding the development of ly 1992 Nov In this report the association of autoimmunity and autoimmune syndromes with lymphoproliferative disorders (LPD) is described in 15 patients. Non-Hodgkin's lymphoma (NHL) developed in 10 patients, Hodgkin's disease (HD) in 3 and chronic lymphocytic leukemia (CLL) in two. In most instances clinical and laboratory phenomena preceded the development/diagnosis of these disorders. Manifestations ranged from the presence of autoantibodies in the serum to the presence of both ill defined or incomplete autoimmune syndromes including cold urticaria, Raynaud's phenomenon, cold agglutinin disease, thyroiditis, nephrotic syndrome and vasculitis to typical systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and even one of scleroderma. It is suggested that in some patients (in)complete clinical manifestations of autoimmunity may precede the development of lymphoid neoplasias. The link between autoimmunity and lymphoproliferative disorders is briefly discussed.
1395763 Bronchiolitis obliterans organizing pneumonia associated with systemic lupus erythematosus 1992 Oct Bronchiolitis obliterans organizing pneumonia (BOOP) is a pathologic entity characterized by the formation of plugs of fibrous tissue in bronchioles and alveolar ducts. It has been described in association with several connective tissue diseases including rheumatoid arthritis, polymyositis-dermatomyositis, and mixed connective tissue disease. Well-documented reports of BOOP in patients with systemic lupus erythematosus (SLE) are limited. We report two patients with SLE who presented with subacute respiratory illnesses due to BOOP, adding further strength to the association of this entity with SLE.